CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh; Evelyn Kuhnt; Lorenz Trümper; Anders Osterborg; Marek Trneny; Lois Shepherd; Devinder S Gill; Jan Walewski; Ruth Pettengell; Ulrich Jaeger; Pier-Luigi Zinzani; Ofer Shpilberg; Stein Kvaloy; Peter de Nully Brown; Rolf Stahel; Noel Milpied; Armando López-Guillermo; Viola Poeschel; Sandra Grass; Markus Loeffler; Niels Murawski; MabThera International Trial (MInT) Group

doi:10.1016/S1470-2045(11)70235-2

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh
, Evelyn Kuhnt
, Lorenz Trümper
, Anders Osterborg
, Marek Trneny
, Lois Shepherd
, Devinder S Gill
, Jan Walewski
, Ruth Pettengell
, Ulrich Jaeger
, Pier-Luigi Zinzani
, Ofer Shpilberg
, Stein Kvaloy
, Peter de Nully Brown
, Rolf Stahel
, Noel Milpied
, Armando López-Guillermo
, Viola Poeschel
, Sandra Grass
, Markus Loeffler

Niels Murawski, MabThera International Trial (MInT) Group

717 Citationer (Scopus)

Abstract

The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.

Originalsprog	Engelsk
Tidsskrift	Lancet Oncology
Vol/bind	12
Udgave nummer	11
Sider (fra-til)	1013-22
Antal sider	10
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(11)70235-2
Status	Udgivet - 2011

Adgang til dokumentet

10.1016/S1470-2045(11)70235-2

Fingeraftryk

Dyk ned i forskningsemnerne om 'CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Pfreundschuh, M., Kuhnt, E., Trümper, L., Osterborg, A., Trneny, M., Shepherd, L., Gill, D. S., Walewski, J., Pettengell, R., Jaeger, U., Zinzani, P.-L., Shpilberg, O., Kvaloy, S., de Nully Brown, P., Stahel, R., Milpied, N., López-Guillermo, A., Poeschel, V., Grass, S., ... MabThera International Trial (MInT) Group (2011). CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncology, 12(11), 1013-22. https://doi.org/10.1016/S1470-2045(11)70235-2

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. / Pfreundschuh, Michael; Kuhnt, Evelyn; Trümper, Lorenz et al.
I: Lancet Oncology, Bind 12, Nr. 11, 2011, s. 1013-22.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Pfreundschuh, M, Kuhnt, E, Trümper, L, Osterborg, A, Trneny, M, Shepherd, L, Gill, DS, Walewski, J, Pettengell, R, Jaeger, U, Zinzani, P-L, Shpilberg, O, Kvaloy, S, de Nully Brown, P, Stahel, R, Milpied, N, López-Guillermo, A, Poeschel, V, Grass, S, Loeffler, M, Murawski, N & MabThera International Trial (MInT) Group 2011, 'CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group', Lancet Oncology, bind 12, nr. 11, s. 1013-22. https://doi.org/10.1016/S1470-2045(11)70235-2

@article{a61bbac5909b496aa5deab7a89294028,

title = "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group",

abstract = "The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.",

keywords = "Adolescent, Adult, Age Factors, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Australia, Canada, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Europe, Humans, Israel, Kaplan-Meier Estimate, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Neoplasm Staging, Prednisone, Proportional Hazards Models, Radiotherapy, Adjuvant, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Vincristine, Young Adult",

author = "Michael Pfreundschuh and Evelyn Kuhnt and Lorenz Tr{\"u}mper and Anders Osterborg and Marek Trneny and Lois Shepherd and Gill, \{Devinder S\} and Jan Walewski and Ruth Pettengell and Ulrich Jaeger and Pier-Luigi Zinzani and Ofer Shpilberg and Stein Kvaloy and \{de Nully Brown\}, Peter and Rolf Stahel and Noel Milpied and Armando L{\'o}pez-Guillermo and Viola Poeschel and Sandra Grass and Markus Loeffler and Niels Murawski and \{MabThera International Trial (MInT) Group\}",

year = "2011",

doi = "10.1016/S1470-2045(11)70235-2",

language = "English",

volume = "12",

pages = "1013--22",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "11",

}

TY - JOUR

T1 - CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

AU - Pfreundschuh, Michael

AU - Kuhnt, Evelyn

AU - Trümper, Lorenz

AU - Osterborg, Anders

AU - Trneny, Marek

AU - Shepherd, Lois

AU - Gill, Devinder S

AU - Walewski, Jan

AU - Pettengell, Ruth

AU - Jaeger, Ulrich

AU - Zinzani, Pier-Luigi

AU - Shpilberg, Ofer

AU - Kvaloy, Stein

AU - de Nully Brown, Peter

AU - Stahel, Rolf

AU - Milpied, Noel

AU - López-Guillermo, Armando

AU - Poeschel, Viola

AU - Grass, Sandra

AU - Loeffler, Markus

AU - Murawski, Niels

AU - MabThera International Trial (MInT) Group

PY - 2011

Y1 - 2011

N2 - The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.

AB - The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.

KW - Adolescent

KW - Adult

KW - Age Factors

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Australia

KW - Canada

KW - Cyclophosphamide

KW - Disease-Free Survival

KW - Doxorubicin

KW - Europe

KW - Humans

KW - Israel

KW - Kaplan-Meier Estimate

KW - Lymphoma, Large B-Cell, Diffuse

KW - Middle Aged

KW - Neoplasm Staging

KW - Prednisone

KW - Proportional Hazards Models

KW - Radiotherapy, Adjuvant

KW - Risk Assessment

KW - Risk Factors

KW - Time Factors

KW - Treatment Outcome

KW - Vincristine

KW - Young Adult

U2 - 10.1016/S1470-2045(11)70235-2

DO - 10.1016/S1470-2045(11)70235-2

M3 - Journal article

C2 - 21940214

SN - 1470-2045

VL - 12

SP - 1013

EP - 1022

JO - Lancet Oncology

JF - Lancet Oncology

IS - 11

ER -